Bli medlem
Bli medlem

Du är här

2016-05-12

Novavax, Inc.: Novavax Receives the Tech Council of Maryland's Chairman's Award

GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc.,
(Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced it received the Tech Council of Maryland's (TCM)
Chairman's Award. The award was announced at the TCM Industry Award
Celebration on May 11, 2016.

The Chairman's Award is presented to a member company or individual that best
exemplifies excellence in Maryland's technology or life science industry.
The Award recognizes a company that is a pillar in the community, not only
through market success or job creation, but by consistently giving back,
getting involved and advancing the climate for innovation.

"Novavax is the embodiment of what we look for when selecting an honoree for
the Chairman's award. The company has built a successful business, employing
450 people in Maryland who are developing vaccines that positively impact
global health, and has played an important role in fostering growth of the
state's life sciences community," said Rene B. LaVigne, TCM chairman-elect
and president and CEO of Iron Bow Technologies. "TCM appreciates Novavax's
significant contributions to the association, the state's economy and
innovations in healthcare."

"I am honored to accept this award on behalf of the entire Novavax team," said
Stanley C. Erck, President and CEO, Novavax. "The Tech Council of Maryland
facilitates a collaborative community of technology and life science
companies who aim to make an impact in our region and beyond. We are thrilled
that this award recognizes the hard work and dedication of our more than 450
SuperNovas, our groundbreaking achievements in developing novel vaccines and
our commitment to the Maryland life science and technology community."

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is
available on the Company's website, novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations

ir@novavax.com
240-268-2000

Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#2011869

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.